Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

Slow e-motion; big things and manners in internet health deb...

Nick Broughton reflects on last month’s debate with Ben Goldacre and shares his thoughts on why it’s important to keep good manners during discussions on social media. One of the more hefty crosses yours truly has to bear at the moment is a grimly devout loyalty to...

Articles

Data protection fines: enhancing patient protection or reduc...

Paul Gershlick discusses data protection fines in the UK and questions whether, with tightening healthcare budgets, they truly benefit the patient. At the beginning of 2012, the Information Commissioner’s Office (the “ICO”) announced that the health sector would be topping…

Articles

Pharma and the culture of technology

Daniel Marovitz discusses the challenges in pharma and technology partnerships, due to the recent culture change and rise in social media. We have all watched the social media revolution. It is one of the most profound changes in the history of...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital